Peptide Antibody Services

Immunizing with a peptide corresponding to a specific region of a protein antigen is a popular method to develop custom antibodies. With this strategy, you only need the amino acid sequence of a predicted/selected epitope within the protein antigen, avoiding homologous regions to minimize cross reactivity with other proteins. 

Antigenic peptides of 10-20 amino acids in length provide optimal epitope diversity while still offering superior specificity compared to immunizing with the full length protein sequence. The peptide is usually conjugated to a carrier protein such as KLH or BSA to enhance stimulation of an immune response. Antibodies are generated against the peptide sequence and the carrier protein. Therefore, the highly specific antibodies directed against the peptide are separated by affinity purification.

Why Use Peptide Antigens for Immunization?

  • Chemical synthesis yields defined epitopes
  • Low probability of cross-reactivity
  • High flexibility in antigen selection
  • Sequence diversity and PTMs can be addressed
  • Easy to synthesize, cost-effective and stable

Applications for Antibody Services

  • Antigen design
  • Production of antigen conjugates
  • Titer determination
  • Hybridoma screening
  • Epitope mapping
  • Blocking peptides

JPT's Antibody Peptide Formats

Immunogen Design

  • Design and production of immunogenic peptides (e.g. KLH, BSA, OVA conjugates or MAP –multiple antigenic peptides)
  • Modified peptides carrying PTMs such as phosphorylation, citrullination, acetylation and more
  • Design supported by data mining, modeling and bioinformatics 

Assay Development

Antibody Development

Process Optimization

  • Peptides as assay control
  • Affinity Purification



  • Expression of Programmed Death Ligand (PD-L1) in Different Tumors. Comparison of Several Current Available Antibody Clones and Antibody Profiling
    Kintsler et al., Annals of Diagnostic Pathology (2019)
  • Der p 5 Allergen from House Dust Mite: First Epitope Mapping of Rabbit IgG Blocking Antibodies
    Lahiani et al., New Microbes and New Infections (2019)
  • Envelope-Specific Epitope Recognition Patterns of HIV Vaccine-Induced IgG Antibodies are Linked to Immunogen Structure and Sequence
    Nadai et al, Front. Immunol (2019)
  • Development of a Novel Fully-Human Anti-CD123 Antibody to Target Acute Myeloid Leukemia
    Baraniaket al, Leukemia Research (2019)
  • Array-In-Well Epitope Mapping of Phage-Displayed Antibodies
    Lamminmäki et al., Epitope Mapping Protocols (2018)
  • Analytical Performance of an Immunoassay to Measure Proenkephalin
    Donato et al, Clinical Biochemistry (2018)

Read more references
Application Notes


"The RV 144 HIV trial is considered as one of first successful HIV vaccine trials. It has become clear that the V2 loop of gp120 is an important site for immunogenicity and protection from HIV infection. The use of JPT’s PepStar™ microarray technology has been very useful for the correlation of the clinical outcome with humoral immune responses. As have the cyclic peptides been from JPT to validate these findings!"
J. Currier, PhD (Walter Reed Army Institute, Rockville, Maryland, USA)


Check our list of products, click and go.

Get a quote